Primary liver cancer (hepatocellular carcinoma) has the fastest-rising cancer incidence of any malignant tumor in the US. It is the third leading cause of cancer-related death worldwide.

The Mount Sinai Medical Center has been at the forefront of clinical management of liver cancer in the United States. The Mount Sinai Hospital is the leading center in the US in terms of number of new liver cancer patients evaluated annually.

Mount Sinai is also a leader in research on liver cancer. As a result our patients often have access to new treatments before they are available elsewhere. Mount Sinai was the largest recruitment site in the country for studies of sorafenib, the first treatment proven to extend life for patients with advanced liver cancer.